Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enhabit Reports First Quarter 2024 Financial Results By: Enhabit, Inc. via Business Wire May 08, 2024 at 16:10 PM EDT Company to host a conference call tomorrow, May 9, 2024, at 10 a.m. EDT Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the first quarter ended March 31, 2024. “Our momentum exiting 2023 and through the first quarter of 2024 instills confidence and excitement in our strategy and team,” said Enhabit’s President and Chief Executive Officer Barb Jacobsmeyer. “Our strong start to 2024 is a result of our team’s continued focus on our operational strategies. Additional frontline clinicians, more and better home health payor contracts and controlling general and administrative expenses were the key drivers of our performance in the first quarter and resulted in sustained consolidated Adjusted EBITDA of $25.3 million in both the first quarter of 2024 and 2023. We are confident we are taking the right steps to drive future growth.” QUARTERLY PERFORMANCE - CONSOLIDATED Net service revenue of $262.4 million Net income attributable to Enhabit, Inc. of $0.2 million Adjusted EBITDA of $25.3 million Earnings per share of $0.01 Adjusted earnings per share of $0.07 RECENT COMPANY HIGHLIGHTS Strong growth in home health Medicare Advantage admissions with non-Medicare admissions up 25.2%, driving total admission growth of 5.3% year over year 38% of non-Medicare visits are now in payor innovation contracts at improved rates Continued recruiting success adding 151 net new full-time nursing hires in the first quarter 30-day hospitalization readmission rate in home health is 20.5% better than the national average 5.6% sequential growth in hospice admissions 53.2% better than the national average for hospice patient visits in last days of life General and administrative expense declined year over year Opened two hospice de novo locations in Texas in March FINANCIAL RESULTS Consolidated ($ in millions, except per share data) Q1 '24 vs. '23 2024 2023 Home health net service revenue $ 213.2 $ 215.8 (1.2 )% Hospice net service revenue 49.2 49.3 (0.2 )% Total net service revenue $ 262.4 $ 265.1 (1.0 )% % of revenue % of revenue Cost of service 51.1 % $ 134.2 50.0 % $ 132.6 1.2 % Gross margin 48.9 % 128.2 50.0 % 132.5 (3.2 )% General and administrative expenses 38.9 % 102.2 40.2 % 106.7 (4.2 )% Total operating expenses 90.1 % $ 236.4 90.3 % $ 239.3 (1.2 )% Net income attributable to noncontrolling interests (0.7 ) (0.5 ) Adjusted EBITDA $ 25.3 $ 25.3 — % Adjusted EBITDA margin 9.6 % 9.5 % Net income attributable to Enhabit, Inc. $ 0.2 $ 2.7 (92.6 )% Reported diluted EPS $ 0.01 $ 0.05 (80.0 )% Adjusted EPS $ 0.07 $ 0.09 (22.2 )% The strategy to increase admissions in payor innovation contracts lessened the impact of mix shift contributing to sustained consolidated Adjusted EBITDA of $25.3 million in both periods presented. The shift to more non-Medicare admissions in home health impacted consolidated revenue and Adjusted EBITDA by approximately $6 million partially offset by approximately $4 million in pricing improvement. SEGMENT RESULTS Home Health ($ in millions) Q1 '24 vs. '23 2024 2023 Net service revenue: Medicare 128.3 146.0 (12.1 )% Non-Medicare 82.6 67.1 23.1 % Private duty(1) 2.3 2.7 (14.8 )% Home health net service revenue 213.2 215.8 (1.2 )% Cost of service 109.9 108.2 1.6 % Gross margin 48.5 % 49.9 % General and administrative expenses 59.5 62.9 (5.4 )% Net income attributable to noncontrolling interests 0.6 0.4 50.0 % Adjusted EBITDA $ 43.2 $ 44.3 (2.5 )% % Adj. EBITDA margin 20.3 % 20.5 % Operational metrics (actual amounts) Medicare: Admissions 25,944 29,285 (11.4 )% Recertifications 17,652 19,938 (11.5 )% Completed episodes 43,171 49,231 (12.3 )% Visits 632,047 723,399 (12.6 )% Visits per episode 14.6 14.7 (0.7 )% Revenue per episode $ 2,972 $ 2,966 0.2 % Non-Medicare: Admissions 30,881 24,658 25.2 % Recertifications 13,489 11,840 13.9 % Visits 571,289 482,301 18.5 % Total: Admissions 56,825 53,943 5.3 % Same-store total admissions growth 5.0 % Recertifications 31,141 31,778 (2.0 )% Same-store total recertifications growth (2.4 )% Visits 1,203,336 1,205,700 (0.2 )% Cost per visit $ 90 $ 88 2.3 % (1) Private duty represents long-term comprehensive hourly nursing medical care. Revenue declined year over year primarily due to the payor mix shift to more non-Medicare admissions (approximately $6 million) partially offset by improved pricing (approximately $4 million). Adjusted EBITDA decreased year over year primarily due to the payor mix shift to more non-Medicare admissions and increased cost of service, offset by a reduction in general and administrative expenses. Cost per visit increased 2.3% year over year primarily due to merit and market rate increases. General and administrative expenses declined year over year primarily due to a new organizational structure implemented in the first quarter of 2023 to align the Company’s sales and operations teams. Hospice ($ in millions) Q1 '24 vs. '23 2024 2023 Net service revenue $ 49.2 $ 49.3 (0.2 )% Cost of service 24.3 24.4 (0.4 )% Gross margin 50.6 % 50.5 % General and administrative expenses 15.7 16.3 (3.7 )% Net income attributable to noncontrolling interests 0.1 0.1 — % Adjusted EBITDA $ 9.1 $ 8.5 7.1 % % Adj. EBITDA margin 18.5 % 17.2 % Operational metrics (actual amounts) Total admissions 3,032 3,122 (2.9 )% Same-store total admissions growth (5.1 )% Patient days 308,542 317,027 (2.7 )% Discharged average length of stay 104 114 (8.8 )% Average daily census 3,391 3,523 (3.7 )% Revenue per patient day $ 159 $ 156 1.9 % Cost per patient day $ 79 $ 77 2.6 % Net service revenue decreased year over year as increased Medicare reimbursement rates were offset by a decrease in patient days. Adjusted EBITDA increased year over year primarily due to a decrease in general and administrative expenses. Cost per day increased 2.6% year over year primarily due to a decrease in patient days. General and administrative expenses declined year over year primarily due to the restructuring of hospice back office staffing in the third quarter of 2023. GUIDANCE The Company reaffirmed its full-year 2024 guidance as follows: ($ in millions, except per share data) 2024 Guidance Net service revenue $1,076 to $1,102 Adjusted EBITDA $98 to $110 Adjusted EPS $0.12 to $0.43 For additional considerations regarding the Company’s 2024 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com. CONFERENCE CALL INFORMATION The Company will host an investor conference call at 10 a.m. EDT on May 9, 2024, to discuss its results for the first quarter of 2024. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/834974223. Following the call, a replay will be available on the Company’s website at http://investors.ehab.com. ABOUT ENHABIT HOME HEALTH & HOSPICE Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 112 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com. OTHER INFORMATION Note regarding presentation and reconciliation of non-GAAP financial measures The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, and Adjusted free cash flow. See “Reconciliations of Non-GAAP Financial Measures” for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Additionally, our Form 10-Q for the three months ended March 31, 2024, provide further information regarding “unusual or nonrecurring items that are not typical of ongoing operations,” a reconciliation item in our Adjusted EBITDA calculation. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies. The Company is unable to reconcile the guidance for Adjusted EBITDA and Adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information. Note regarding presentation of same-store comparisons The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations. Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited) Three Months Ended March 31, 2024 2023 ($ in millions, except per share data) Net service revenue $ 262.4 $ 265.1 Cost of service, excluding depreciation and amortization 134.2 132.6 General and administrative expenses 107.5 110.5 Depreciation and amortization 7.8 7.8 Operating income 12.9 14.2 Interest expense and amortization of debt discounts and fees 11.1 9.5 Income before income taxes and noncontrolling interests 1.8 4.7 Income tax expense 0.9 1.5 Net income 0.9 3.2 Less: Net income attributable to noncontrolling interests 0.7 0.5 Net income attributable to Enhabit, Inc. $ 0.2 $ 2.7 Weighted average common shares outstanding: Basic 50.1 49.8 Diluted 50.4 50.1 Earnings per common share: Basic earnings per share attributable to Enhabit, Inc. common stockholders $ 0.01 $ 0.05 Diluted earnings per share attributable to Enhabit, Inc. common stockholders $ 0.01 $ 0.05 Enhabit, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited) March 31, 2024 December 31, 2023 ($ in millions) Assets Current assets: Cash and cash equivalents $ 36.5 $ 27.4 Restricted cash 2.9 2.4 Accounts receivable, net of allowances 174.3 164.7 Prepaid expenses and other current assets 12.4 15.6 Total current assets 226.1 210.1 Property and equipment, net 20.6 19.0 Operating lease right-of-use assets 57.0 57.5 Goodwill 1,061.7 1,061.7 Intangible assets, net 74.6 80.0 Other long-term assets 5.2 5.3 Total assets $ 1,445.2 $ 1,433.6 Liabilities and stockholders’ equity Current liabilities: Current portion of long-term debt $ 22.8 $ 22.5 Current operating lease liabilities 11.2 11.8 Accounts payable 9.0 7.6 Accrued payroll 49.1 38.5 Refunds due patients and other third-party payors 10.5 8.2 Accrued medical insurance 7.4 8.4 Other current liabilities 40.5 40.7 Total current liabilities 150.5 137.7 Long-term debt, net of current portion 526.7 530.1 Long-term operating lease liabilities, net of current portion 45.8 45.7 Deferred income tax liabilities 17.0 17.1 Other long-term liabilities 0.2 1.3 Total liabilities 740.2 731.9 Redeemable noncontrolling interests 5.0 5.0 Stockholders’ equity: Total Enhabit, Inc. stockholders’ equity 672.3 669.7 Noncontrolling interests 27.7 27.0 Total stockholders’ equity 700.0 696.7 Total liabilities and stockholders’ equity $ 1,445.2 $ 1,433.6 Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months Ended March 31, 2024 2023 ($ in millions) Cash flows from operating activities: Net income $ 0.9 $ 3.2 Adjustments to reconcile net income to net cash provided by operating activities Depreciation and amortization 7.8 7.8 Amortization of debt related costs 0.4 0.3 Stock-based compensation 1.8 1.5 Deferred tax (benefit) expense (0.5 ) 0.3 Other (0.3 ) — Changes in assets and liabilities, net of acquisitions Accounts receivable, net of allowances (9.7 ) (6.7 ) Prepaid expenses and other assets 3.7 18.1 Accounts payable 1.4 2.3 Accrued payroll 10.7 12.2 Other liabilities 1.1 (9.4 ) Net cash provided by operating activities 17.3 29.6 Cash flows from investing activities: Acquisition of businesses, net of cash acquired — (2.8 ) Purchases of property and equipment, including capitalized software costs (1.8 ) (0.6 ) Other 0.7 0.2 Net cash used in investing activities (1.1 ) (3.2 ) Cash flows from financing activities: Principal payments on debt (5.0 ) (5.0 ) Payments on revolving credit facility — (5.0 ) Principal payments under finance lease obligations (1.0 ) (1.0 ) Distributions paid to noncontrolling interests of consolidated affiliates — (2.5 ) Other (0.6 ) (0.5 ) Net cash used in financing activities (6.6 ) (14.0 ) Increase in cash, cash equivalents, and restricted cash 9.6 12.4 Cash, cash equivalents, and restricted cash at beginning of year 29.8 27.2 Cash, cash equivalents, and restricted cash at end of period $ 39.4 $ 39.6 Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Diluted Earnings Per Share to Adjusted Earnings Per Share Three Months Ended March 31, 2024 2023 Diluted earnings per share, as reported $ 0.01 $ 0.05 Adjustments, net of tax: Unusual or nonrecurring items that are not typical of ongoing operations(1) 0.06 0.03 Income tax adjustments(2) 0.01 0.01 Adjusted earnings per share(3) $ 0.07 $ 0.09 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. (2) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. (3) Adjusted EPS may not sum due to rounding. Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share Three Months Ended March 31, 2024 Adjustments As Reported Unusual or nonrecurring items that are not typical of ongoing operations Income tax Adjustments(3) As Adjusted ($ in millions, except per share data) Adjusted EBITDA(1) $ 25.3 $ — $ — $ 25.3 Interest expense and amortization of debt discounts and fees (11.1 ) — — (11.1 ) Depreciation and amortization (7.8 ) — — (7.8 ) Unusual or nonrecurring items that are not typical of ongoing operations(2) (3.7 ) 3.7 — — Stock-based compensation (1.8 ) — — (1.8 ) Gain on disposal or impairment of assets 0.2 — — 0.2 Income before income taxes 1.1 3.7 — 4.8 Income tax expense (0.9 ) (0.9 ) 0.6 (1.2 ) Net income attributable to Enhabit, Inc. $ 0.2 $ 2.8 $ 0.6 $ 3.6 Diluted EPS(4) $ 0.01 $ 0.06 $ 0.01 $ 0.07 Diluted shares 50.4 50.4 (1) Reconciliation to GAAP provided below. (2) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism. (3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. (4) Diluted EPS may not sum due to rounding. Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share Three Months Ended March 31, 2023 Adjustments As Reported Unusual or nonrecurring items that are not typical of ongoing operations Income Tax Adjustments(3) As Adjusted ($ in millions, except per share data) Adjusted EBITDA(1) $ 25.3 $ — $ — $ 25.3 Depreciation and amortization (7.8 ) — — (7.8 ) Interest expense and amortization of debt discounts and fees (9.5 ) — — (9.5 ) Stock-based compensation (1.5 ) — — (1.5 ) Unusual or nonrecurring items that are not typical of ongoing operations(2) (2.3 ) 2.3 — — Income before income taxes 4.2 2.3 — 6.5 Income tax expense (1.5 ) (0.6 ) 0.4 (1.7 ) Net income attributable to Enhabit, Inc. $ 2.7 $ 1.7 $ 0.4 $ 4.8 Diluted EPS(4) $ 0.05 $ 0.03 $ 0.01 $ 0.09 Diluted shares 50.1 50.1 (1) Reconciliation to GAAP provided below. (2) Unusual or nonrecurring items in Q1 2023 include nonroutine litigation, shareholder activism and standalone transition costs. (3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. (4) Diluted EPS may not sum due to rounding. Reconciliation of Net Income to Adjusted EBITDA Three Months Ended March 31, 2024 2023 ($ in millions) Net income $ 0.9 $ 3.2 Income tax expense 0.9 1.5 Interest expense and amortization of debt discounts and fees 11.1 9.5 Depreciation and amortization 7.8 7.8 Gain on disposal or impairment of assets (0.2 ) — Stock-based compensation 1.8 1.5 Net income attributable to noncontrolling interests (0.7 ) (0.5 ) Unusual or nonrecurring items that are not typical of ongoing operations(1) 3.7 2.3 Adjusted EBITDA $ 25.3 $ 25.3 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA Three Months Ended March 31, 2024 2023 ($ in millions) Net cash provided by operating activities $ 17.3 $ 29.6 Current portion of income tax expense 1.4 1.2 Interest expense, excluding amortization of debt discounts and fees 10.7 9.5 Change in assets and liabilities, excluding derivative instrument (7.2 ) (16.5 ) Net income attributable to noncontrolling interests (0.7 ) (0.5 ) Unusual or nonrecurring items that are not typical of ongoing operations(1) 3.7 2.3 Other 0.1 (0.3 ) Adjusted EBITDA $ 25.3 $ 25.3 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow Three Months Ended March 31, 2024 2023 ($ in millions) Net cash provided by operating activities $ 17.3 $ 29.6 Unusual or nonrecurring items that are not typical of ongoing operations(1) 3.7 2.3 Capital expenditures for maintenance (1.8 ) (0.6 ) Other working capital adjustments (0.6 ) (0.5 ) Distributions paid to noncontrolling interests of consolidated affiliates — (2.5 ) Adjusted free cash flow $ 18.6 $ 28.3 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. Reconciliation of Gross Margin to Adjusted EBITDA Margin Three Months Ended March 31, 2024 2023 Gross margin as a percentage of revenue 48.9 % 50.0 % General and administrative expenses (41.0 )% (41.7 )% Unusual or nonrecurring items that are not typical of ongoing operations(1) 1.4 % 0.9 % Stock-based compensation 0.7 % 0.5 % Noncontrolling interests (0.3 )% (0.2 )% Gain on disposal or impairment of assets (0.1 )% — % Adjusted EBITDA margin 9.6 % 9.5 % (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. FORWARD-LOOKING STATEMENTS Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and health care professionals; potential disruptions or breaches of our or our vendors’, payors’, and other contract counterparties’ information systems; the outcome of litigation; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; our ability to control costs, particularly labor and employee benefit costs; and impacts resulting from the announcement of the conclusion of the strategic review process. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company’s website at http://investors.ehab.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240508764297/en/Contacts Investor relations contact Crissy Carlisle investorrelations@ehab.com 469-860-6061 Media contact Erin Volbeda media@ehab.com 972-338-5141 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Enhabit Reports First Quarter 2024 Financial Results By: Enhabit, Inc. via Business Wire May 08, 2024 at 16:10 PM EDT Company to host a conference call tomorrow, May 9, 2024, at 10 a.m. EDT Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the first quarter ended March 31, 2024. “Our momentum exiting 2023 and through the first quarter of 2024 instills confidence and excitement in our strategy and team,” said Enhabit’s President and Chief Executive Officer Barb Jacobsmeyer. “Our strong start to 2024 is a result of our team’s continued focus on our operational strategies. Additional frontline clinicians, more and better home health payor contracts and controlling general and administrative expenses were the key drivers of our performance in the first quarter and resulted in sustained consolidated Adjusted EBITDA of $25.3 million in both the first quarter of 2024 and 2023. We are confident we are taking the right steps to drive future growth.” QUARTERLY PERFORMANCE - CONSOLIDATED Net service revenue of $262.4 million Net income attributable to Enhabit, Inc. of $0.2 million Adjusted EBITDA of $25.3 million Earnings per share of $0.01 Adjusted earnings per share of $0.07 RECENT COMPANY HIGHLIGHTS Strong growth in home health Medicare Advantage admissions with non-Medicare admissions up 25.2%, driving total admission growth of 5.3% year over year 38% of non-Medicare visits are now in payor innovation contracts at improved rates Continued recruiting success adding 151 net new full-time nursing hires in the first quarter 30-day hospitalization readmission rate in home health is 20.5% better than the national average 5.6% sequential growth in hospice admissions 53.2% better than the national average for hospice patient visits in last days of life General and administrative expense declined year over year Opened two hospice de novo locations in Texas in March FINANCIAL RESULTS Consolidated ($ in millions, except per share data) Q1 '24 vs. '23 2024 2023 Home health net service revenue $ 213.2 $ 215.8 (1.2 )% Hospice net service revenue 49.2 49.3 (0.2 )% Total net service revenue $ 262.4 $ 265.1 (1.0 )% % of revenue % of revenue Cost of service 51.1 % $ 134.2 50.0 % $ 132.6 1.2 % Gross margin 48.9 % 128.2 50.0 % 132.5 (3.2 )% General and administrative expenses 38.9 % 102.2 40.2 % 106.7 (4.2 )% Total operating expenses 90.1 % $ 236.4 90.3 % $ 239.3 (1.2 )% Net income attributable to noncontrolling interests (0.7 ) (0.5 ) Adjusted EBITDA $ 25.3 $ 25.3 — % Adjusted EBITDA margin 9.6 % 9.5 % Net income attributable to Enhabit, Inc. $ 0.2 $ 2.7 (92.6 )% Reported diluted EPS $ 0.01 $ 0.05 (80.0 )% Adjusted EPS $ 0.07 $ 0.09 (22.2 )% The strategy to increase admissions in payor innovation contracts lessened the impact of mix shift contributing to sustained consolidated Adjusted EBITDA of $25.3 million in both periods presented. The shift to more non-Medicare admissions in home health impacted consolidated revenue and Adjusted EBITDA by approximately $6 million partially offset by approximately $4 million in pricing improvement. SEGMENT RESULTS Home Health ($ in millions) Q1 '24 vs. '23 2024 2023 Net service revenue: Medicare 128.3 146.0 (12.1 )% Non-Medicare 82.6 67.1 23.1 % Private duty(1) 2.3 2.7 (14.8 )% Home health net service revenue 213.2 215.8 (1.2 )% Cost of service 109.9 108.2 1.6 % Gross margin 48.5 % 49.9 % General and administrative expenses 59.5 62.9 (5.4 )% Net income attributable to noncontrolling interests 0.6 0.4 50.0 % Adjusted EBITDA $ 43.2 $ 44.3 (2.5 )% % Adj. EBITDA margin 20.3 % 20.5 % Operational metrics (actual amounts) Medicare: Admissions 25,944 29,285 (11.4 )% Recertifications 17,652 19,938 (11.5 )% Completed episodes 43,171 49,231 (12.3 )% Visits 632,047 723,399 (12.6 )% Visits per episode 14.6 14.7 (0.7 )% Revenue per episode $ 2,972 $ 2,966 0.2 % Non-Medicare: Admissions 30,881 24,658 25.2 % Recertifications 13,489 11,840 13.9 % Visits 571,289 482,301 18.5 % Total: Admissions 56,825 53,943 5.3 % Same-store total admissions growth 5.0 % Recertifications 31,141 31,778 (2.0 )% Same-store total recertifications growth (2.4 )% Visits 1,203,336 1,205,700 (0.2 )% Cost per visit $ 90 $ 88 2.3 % (1) Private duty represents long-term comprehensive hourly nursing medical care. Revenue declined year over year primarily due to the payor mix shift to more non-Medicare admissions (approximately $6 million) partially offset by improved pricing (approximately $4 million). Adjusted EBITDA decreased year over year primarily due to the payor mix shift to more non-Medicare admissions and increased cost of service, offset by a reduction in general and administrative expenses. Cost per visit increased 2.3% year over year primarily due to merit and market rate increases. General and administrative expenses declined year over year primarily due to a new organizational structure implemented in the first quarter of 2023 to align the Company’s sales and operations teams. Hospice ($ in millions) Q1 '24 vs. '23 2024 2023 Net service revenue $ 49.2 $ 49.3 (0.2 )% Cost of service 24.3 24.4 (0.4 )% Gross margin 50.6 % 50.5 % General and administrative expenses 15.7 16.3 (3.7 )% Net income attributable to noncontrolling interests 0.1 0.1 — % Adjusted EBITDA $ 9.1 $ 8.5 7.1 % % Adj. EBITDA margin 18.5 % 17.2 % Operational metrics (actual amounts) Total admissions 3,032 3,122 (2.9 )% Same-store total admissions growth (5.1 )% Patient days 308,542 317,027 (2.7 )% Discharged average length of stay 104 114 (8.8 )% Average daily census 3,391 3,523 (3.7 )% Revenue per patient day $ 159 $ 156 1.9 % Cost per patient day $ 79 $ 77 2.6 % Net service revenue decreased year over year as increased Medicare reimbursement rates were offset by a decrease in patient days. Adjusted EBITDA increased year over year primarily due to a decrease in general and administrative expenses. Cost per day increased 2.6% year over year primarily due to a decrease in patient days. General and administrative expenses declined year over year primarily due to the restructuring of hospice back office staffing in the third quarter of 2023. GUIDANCE The Company reaffirmed its full-year 2024 guidance as follows: ($ in millions, except per share data) 2024 Guidance Net service revenue $1,076 to $1,102 Adjusted EBITDA $98 to $110 Adjusted EPS $0.12 to $0.43 For additional considerations regarding the Company’s 2024 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com. CONFERENCE CALL INFORMATION The Company will host an investor conference call at 10 a.m. EDT on May 9, 2024, to discuss its results for the first quarter of 2024. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/834974223. Following the call, a replay will be available on the Company’s website at http://investors.ehab.com. ABOUT ENHABIT HOME HEALTH & HOSPICE Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 112 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com. OTHER INFORMATION Note regarding presentation and reconciliation of non-GAAP financial measures The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, and Adjusted free cash flow. See “Reconciliations of Non-GAAP Financial Measures” for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Additionally, our Form 10-Q for the three months ended March 31, 2024, provide further information regarding “unusual or nonrecurring items that are not typical of ongoing operations,” a reconciliation item in our Adjusted EBITDA calculation. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies. The Company is unable to reconcile the guidance for Adjusted EBITDA and Adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information. Note regarding presentation of same-store comparisons The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations. Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited) Three Months Ended March 31, 2024 2023 ($ in millions, except per share data) Net service revenue $ 262.4 $ 265.1 Cost of service, excluding depreciation and amortization 134.2 132.6 General and administrative expenses 107.5 110.5 Depreciation and amortization 7.8 7.8 Operating income 12.9 14.2 Interest expense and amortization of debt discounts and fees 11.1 9.5 Income before income taxes and noncontrolling interests 1.8 4.7 Income tax expense 0.9 1.5 Net income 0.9 3.2 Less: Net income attributable to noncontrolling interests 0.7 0.5 Net income attributable to Enhabit, Inc. $ 0.2 $ 2.7 Weighted average common shares outstanding: Basic 50.1 49.8 Diluted 50.4 50.1 Earnings per common share: Basic earnings per share attributable to Enhabit, Inc. common stockholders $ 0.01 $ 0.05 Diluted earnings per share attributable to Enhabit, Inc. common stockholders $ 0.01 $ 0.05 Enhabit, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited) March 31, 2024 December 31, 2023 ($ in millions) Assets Current assets: Cash and cash equivalents $ 36.5 $ 27.4 Restricted cash 2.9 2.4 Accounts receivable, net of allowances 174.3 164.7 Prepaid expenses and other current assets 12.4 15.6 Total current assets 226.1 210.1 Property and equipment, net 20.6 19.0 Operating lease right-of-use assets 57.0 57.5 Goodwill 1,061.7 1,061.7 Intangible assets, net 74.6 80.0 Other long-term assets 5.2 5.3 Total assets $ 1,445.2 $ 1,433.6 Liabilities and stockholders’ equity Current liabilities: Current portion of long-term debt $ 22.8 $ 22.5 Current operating lease liabilities 11.2 11.8 Accounts payable 9.0 7.6 Accrued payroll 49.1 38.5 Refunds due patients and other third-party payors 10.5 8.2 Accrued medical insurance 7.4 8.4 Other current liabilities 40.5 40.7 Total current liabilities 150.5 137.7 Long-term debt, net of current portion 526.7 530.1 Long-term operating lease liabilities, net of current portion 45.8 45.7 Deferred income tax liabilities 17.0 17.1 Other long-term liabilities 0.2 1.3 Total liabilities 740.2 731.9 Redeemable noncontrolling interests 5.0 5.0 Stockholders’ equity: Total Enhabit, Inc. stockholders’ equity 672.3 669.7 Noncontrolling interests 27.7 27.0 Total stockholders’ equity 700.0 696.7 Total liabilities and stockholders’ equity $ 1,445.2 $ 1,433.6 Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months Ended March 31, 2024 2023 ($ in millions) Cash flows from operating activities: Net income $ 0.9 $ 3.2 Adjustments to reconcile net income to net cash provided by operating activities Depreciation and amortization 7.8 7.8 Amortization of debt related costs 0.4 0.3 Stock-based compensation 1.8 1.5 Deferred tax (benefit) expense (0.5 ) 0.3 Other (0.3 ) — Changes in assets and liabilities, net of acquisitions Accounts receivable, net of allowances (9.7 ) (6.7 ) Prepaid expenses and other assets 3.7 18.1 Accounts payable 1.4 2.3 Accrued payroll 10.7 12.2 Other liabilities 1.1 (9.4 ) Net cash provided by operating activities 17.3 29.6 Cash flows from investing activities: Acquisition of businesses, net of cash acquired — (2.8 ) Purchases of property and equipment, including capitalized software costs (1.8 ) (0.6 ) Other 0.7 0.2 Net cash used in investing activities (1.1 ) (3.2 ) Cash flows from financing activities: Principal payments on debt (5.0 ) (5.0 ) Payments on revolving credit facility — (5.0 ) Principal payments under finance lease obligations (1.0 ) (1.0 ) Distributions paid to noncontrolling interests of consolidated affiliates — (2.5 ) Other (0.6 ) (0.5 ) Net cash used in financing activities (6.6 ) (14.0 ) Increase in cash, cash equivalents, and restricted cash 9.6 12.4 Cash, cash equivalents, and restricted cash at beginning of year 29.8 27.2 Cash, cash equivalents, and restricted cash at end of period $ 39.4 $ 39.6 Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Diluted Earnings Per Share to Adjusted Earnings Per Share Three Months Ended March 31, 2024 2023 Diluted earnings per share, as reported $ 0.01 $ 0.05 Adjustments, net of tax: Unusual or nonrecurring items that are not typical of ongoing operations(1) 0.06 0.03 Income tax adjustments(2) 0.01 0.01 Adjusted earnings per share(3) $ 0.07 $ 0.09 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. (2) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. (3) Adjusted EPS may not sum due to rounding. Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share Three Months Ended March 31, 2024 Adjustments As Reported Unusual or nonrecurring items that are not typical of ongoing operations Income tax Adjustments(3) As Adjusted ($ in millions, except per share data) Adjusted EBITDA(1) $ 25.3 $ — $ — $ 25.3 Interest expense and amortization of debt discounts and fees (11.1 ) — — (11.1 ) Depreciation and amortization (7.8 ) — — (7.8 ) Unusual or nonrecurring items that are not typical of ongoing operations(2) (3.7 ) 3.7 — — Stock-based compensation (1.8 ) — — (1.8 ) Gain on disposal or impairment of assets 0.2 — — 0.2 Income before income taxes 1.1 3.7 — 4.8 Income tax expense (0.9 ) (0.9 ) 0.6 (1.2 ) Net income attributable to Enhabit, Inc. $ 0.2 $ 2.8 $ 0.6 $ 3.6 Diluted EPS(4) $ 0.01 $ 0.06 $ 0.01 $ 0.07 Diluted shares 50.4 50.4 (1) Reconciliation to GAAP provided below. (2) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism. (3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. (4) Diluted EPS may not sum due to rounding. Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share Three Months Ended March 31, 2023 Adjustments As Reported Unusual or nonrecurring items that are not typical of ongoing operations Income Tax Adjustments(3) As Adjusted ($ in millions, except per share data) Adjusted EBITDA(1) $ 25.3 $ — $ — $ 25.3 Depreciation and amortization (7.8 ) — — (7.8 ) Interest expense and amortization of debt discounts and fees (9.5 ) — — (9.5 ) Stock-based compensation (1.5 ) — — (1.5 ) Unusual or nonrecurring items that are not typical of ongoing operations(2) (2.3 ) 2.3 — — Income before income taxes 4.2 2.3 — 6.5 Income tax expense (1.5 ) (0.6 ) 0.4 (1.7 ) Net income attributable to Enhabit, Inc. $ 2.7 $ 1.7 $ 0.4 $ 4.8 Diluted EPS(4) $ 0.05 $ 0.03 $ 0.01 $ 0.09 Diluted shares 50.1 50.1 (1) Reconciliation to GAAP provided below. (2) Unusual or nonrecurring items in Q1 2023 include nonroutine litigation, shareholder activism and standalone transition costs. (3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. (4) Diluted EPS may not sum due to rounding. Reconciliation of Net Income to Adjusted EBITDA Three Months Ended March 31, 2024 2023 ($ in millions) Net income $ 0.9 $ 3.2 Income tax expense 0.9 1.5 Interest expense and amortization of debt discounts and fees 11.1 9.5 Depreciation and amortization 7.8 7.8 Gain on disposal or impairment of assets (0.2 ) — Stock-based compensation 1.8 1.5 Net income attributable to noncontrolling interests (0.7 ) (0.5 ) Unusual or nonrecurring items that are not typical of ongoing operations(1) 3.7 2.3 Adjusted EBITDA $ 25.3 $ 25.3 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA Three Months Ended March 31, 2024 2023 ($ in millions) Net cash provided by operating activities $ 17.3 $ 29.6 Current portion of income tax expense 1.4 1.2 Interest expense, excluding amortization of debt discounts and fees 10.7 9.5 Change in assets and liabilities, excluding derivative instrument (7.2 ) (16.5 ) Net income attributable to noncontrolling interests (0.7 ) (0.5 ) Unusual or nonrecurring items that are not typical of ongoing operations(1) 3.7 2.3 Other 0.1 (0.3 ) Adjusted EBITDA $ 25.3 $ 25.3 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow Three Months Ended March 31, 2024 2023 ($ in millions) Net cash provided by operating activities $ 17.3 $ 29.6 Unusual or nonrecurring items that are not typical of ongoing operations(1) 3.7 2.3 Capital expenditures for maintenance (1.8 ) (0.6 ) Other working capital adjustments (0.6 ) (0.5 ) Distributions paid to noncontrolling interests of consolidated affiliates — (2.5 ) Adjusted free cash flow $ 18.6 $ 28.3 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. Reconciliation of Gross Margin to Adjusted EBITDA Margin Three Months Ended March 31, 2024 2023 Gross margin as a percentage of revenue 48.9 % 50.0 % General and administrative expenses (41.0 )% (41.7 )% Unusual or nonrecurring items that are not typical of ongoing operations(1) 1.4 % 0.9 % Stock-based compensation 0.7 % 0.5 % Noncontrolling interests (0.3 )% (0.2 )% Gain on disposal or impairment of assets (0.1 )% — % Adjusted EBITDA margin 9.6 % 9.5 % (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. FORWARD-LOOKING STATEMENTS Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and health care professionals; potential disruptions or breaches of our or our vendors’, payors’, and other contract counterparties’ information systems; the outcome of litigation; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; our ability to control costs, particularly labor and employee benefit costs; and impacts resulting from the announcement of the conclusion of the strategic review process. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company’s website at http://investors.ehab.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240508764297/en/Contacts Investor relations contact Crissy Carlisle investorrelations@ehab.com 469-860-6061 Media contact Erin Volbeda media@ehab.com 972-338-5141
Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the first quarter ended March 31, 2024. “Our momentum exiting 2023 and through the first quarter of 2024 instills confidence and excitement in our strategy and team,” said Enhabit’s President and Chief Executive Officer Barb Jacobsmeyer. “Our strong start to 2024 is a result of our team’s continued focus on our operational strategies. Additional frontline clinicians, more and better home health payor contracts and controlling general and administrative expenses were the key drivers of our performance in the first quarter and resulted in sustained consolidated Adjusted EBITDA of $25.3 million in both the first quarter of 2024 and 2023. We are confident we are taking the right steps to drive future growth.” QUARTERLY PERFORMANCE - CONSOLIDATED Net service revenue of $262.4 million Net income attributable to Enhabit, Inc. of $0.2 million Adjusted EBITDA of $25.3 million Earnings per share of $0.01 Adjusted earnings per share of $0.07 RECENT COMPANY HIGHLIGHTS Strong growth in home health Medicare Advantage admissions with non-Medicare admissions up 25.2%, driving total admission growth of 5.3% year over year 38% of non-Medicare visits are now in payor innovation contracts at improved rates Continued recruiting success adding 151 net new full-time nursing hires in the first quarter 30-day hospitalization readmission rate in home health is 20.5% better than the national average 5.6% sequential growth in hospice admissions 53.2% better than the national average for hospice patient visits in last days of life General and administrative expense declined year over year Opened two hospice de novo locations in Texas in March FINANCIAL RESULTS Consolidated ($ in millions, except per share data) Q1 '24 vs. '23 2024 2023 Home health net service revenue $ 213.2 $ 215.8 (1.2 )% Hospice net service revenue 49.2 49.3 (0.2 )% Total net service revenue $ 262.4 $ 265.1 (1.0 )% % of revenue % of revenue Cost of service 51.1 % $ 134.2 50.0 % $ 132.6 1.2 % Gross margin 48.9 % 128.2 50.0 % 132.5 (3.2 )% General and administrative expenses 38.9 % 102.2 40.2 % 106.7 (4.2 )% Total operating expenses 90.1 % $ 236.4 90.3 % $ 239.3 (1.2 )% Net income attributable to noncontrolling interests (0.7 ) (0.5 ) Adjusted EBITDA $ 25.3 $ 25.3 — % Adjusted EBITDA margin 9.6 % 9.5 % Net income attributable to Enhabit, Inc. $ 0.2 $ 2.7 (92.6 )% Reported diluted EPS $ 0.01 $ 0.05 (80.0 )% Adjusted EPS $ 0.07 $ 0.09 (22.2 )% The strategy to increase admissions in payor innovation contracts lessened the impact of mix shift contributing to sustained consolidated Adjusted EBITDA of $25.3 million in both periods presented. The shift to more non-Medicare admissions in home health impacted consolidated revenue and Adjusted EBITDA by approximately $6 million partially offset by approximately $4 million in pricing improvement. SEGMENT RESULTS Home Health ($ in millions) Q1 '24 vs. '23 2024 2023 Net service revenue: Medicare 128.3 146.0 (12.1 )% Non-Medicare 82.6 67.1 23.1 % Private duty(1) 2.3 2.7 (14.8 )% Home health net service revenue 213.2 215.8 (1.2 )% Cost of service 109.9 108.2 1.6 % Gross margin 48.5 % 49.9 % General and administrative expenses 59.5 62.9 (5.4 )% Net income attributable to noncontrolling interests 0.6 0.4 50.0 % Adjusted EBITDA $ 43.2 $ 44.3 (2.5 )% % Adj. EBITDA margin 20.3 % 20.5 % Operational metrics (actual amounts) Medicare: Admissions 25,944 29,285 (11.4 )% Recertifications 17,652 19,938 (11.5 )% Completed episodes 43,171 49,231 (12.3 )% Visits 632,047 723,399 (12.6 )% Visits per episode 14.6 14.7 (0.7 )% Revenue per episode $ 2,972 $ 2,966 0.2 % Non-Medicare: Admissions 30,881 24,658 25.2 % Recertifications 13,489 11,840 13.9 % Visits 571,289 482,301 18.5 % Total: Admissions 56,825 53,943 5.3 % Same-store total admissions growth 5.0 % Recertifications 31,141 31,778 (2.0 )% Same-store total recertifications growth (2.4 )% Visits 1,203,336 1,205,700 (0.2 )% Cost per visit $ 90 $ 88 2.3 % (1) Private duty represents long-term comprehensive hourly nursing medical care. Revenue declined year over year primarily due to the payor mix shift to more non-Medicare admissions (approximately $6 million) partially offset by improved pricing (approximately $4 million). Adjusted EBITDA decreased year over year primarily due to the payor mix shift to more non-Medicare admissions and increased cost of service, offset by a reduction in general and administrative expenses. Cost per visit increased 2.3% year over year primarily due to merit and market rate increases. General and administrative expenses declined year over year primarily due to a new organizational structure implemented in the first quarter of 2023 to align the Company’s sales and operations teams. Hospice ($ in millions) Q1 '24 vs. '23 2024 2023 Net service revenue $ 49.2 $ 49.3 (0.2 )% Cost of service 24.3 24.4 (0.4 )% Gross margin 50.6 % 50.5 % General and administrative expenses 15.7 16.3 (3.7 )% Net income attributable to noncontrolling interests 0.1 0.1 — % Adjusted EBITDA $ 9.1 $ 8.5 7.1 % % Adj. EBITDA margin 18.5 % 17.2 % Operational metrics (actual amounts) Total admissions 3,032 3,122 (2.9 )% Same-store total admissions growth (5.1 )% Patient days 308,542 317,027 (2.7 )% Discharged average length of stay 104 114 (8.8 )% Average daily census 3,391 3,523 (3.7 )% Revenue per patient day $ 159 $ 156 1.9 % Cost per patient day $ 79 $ 77 2.6 % Net service revenue decreased year over year as increased Medicare reimbursement rates were offset by a decrease in patient days. Adjusted EBITDA increased year over year primarily due to a decrease in general and administrative expenses. Cost per day increased 2.6% year over year primarily due to a decrease in patient days. General and administrative expenses declined year over year primarily due to the restructuring of hospice back office staffing in the third quarter of 2023. GUIDANCE The Company reaffirmed its full-year 2024 guidance as follows: ($ in millions, except per share data) 2024 Guidance Net service revenue $1,076 to $1,102 Adjusted EBITDA $98 to $110 Adjusted EPS $0.12 to $0.43 For additional considerations regarding the Company’s 2024 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com. CONFERENCE CALL INFORMATION The Company will host an investor conference call at 10 a.m. EDT on May 9, 2024, to discuss its results for the first quarter of 2024. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/834974223. Following the call, a replay will be available on the Company’s website at http://investors.ehab.com. ABOUT ENHABIT HOME HEALTH & HOSPICE Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 112 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com. OTHER INFORMATION Note regarding presentation and reconciliation of non-GAAP financial measures The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, and Adjusted free cash flow. See “Reconciliations of Non-GAAP Financial Measures” for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Additionally, our Form 10-Q for the three months ended March 31, 2024, provide further information regarding “unusual or nonrecurring items that are not typical of ongoing operations,” a reconciliation item in our Adjusted EBITDA calculation. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies. The Company is unable to reconcile the guidance for Adjusted EBITDA and Adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information. Note regarding presentation of same-store comparisons The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations. Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited) Three Months Ended March 31, 2024 2023 ($ in millions, except per share data) Net service revenue $ 262.4 $ 265.1 Cost of service, excluding depreciation and amortization 134.2 132.6 General and administrative expenses 107.5 110.5 Depreciation and amortization 7.8 7.8 Operating income 12.9 14.2 Interest expense and amortization of debt discounts and fees 11.1 9.5 Income before income taxes and noncontrolling interests 1.8 4.7 Income tax expense 0.9 1.5 Net income 0.9 3.2 Less: Net income attributable to noncontrolling interests 0.7 0.5 Net income attributable to Enhabit, Inc. $ 0.2 $ 2.7 Weighted average common shares outstanding: Basic 50.1 49.8 Diluted 50.4 50.1 Earnings per common share: Basic earnings per share attributable to Enhabit, Inc. common stockholders $ 0.01 $ 0.05 Diluted earnings per share attributable to Enhabit, Inc. common stockholders $ 0.01 $ 0.05 Enhabit, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited) March 31, 2024 December 31, 2023 ($ in millions) Assets Current assets: Cash and cash equivalents $ 36.5 $ 27.4 Restricted cash 2.9 2.4 Accounts receivable, net of allowances 174.3 164.7 Prepaid expenses and other current assets 12.4 15.6 Total current assets 226.1 210.1 Property and equipment, net 20.6 19.0 Operating lease right-of-use assets 57.0 57.5 Goodwill 1,061.7 1,061.7 Intangible assets, net 74.6 80.0 Other long-term assets 5.2 5.3 Total assets $ 1,445.2 $ 1,433.6 Liabilities and stockholders’ equity Current liabilities: Current portion of long-term debt $ 22.8 $ 22.5 Current operating lease liabilities 11.2 11.8 Accounts payable 9.0 7.6 Accrued payroll 49.1 38.5 Refunds due patients and other third-party payors 10.5 8.2 Accrued medical insurance 7.4 8.4 Other current liabilities 40.5 40.7 Total current liabilities 150.5 137.7 Long-term debt, net of current portion 526.7 530.1 Long-term operating lease liabilities, net of current portion 45.8 45.7 Deferred income tax liabilities 17.0 17.1 Other long-term liabilities 0.2 1.3 Total liabilities 740.2 731.9 Redeemable noncontrolling interests 5.0 5.0 Stockholders’ equity: Total Enhabit, Inc. stockholders’ equity 672.3 669.7 Noncontrolling interests 27.7 27.0 Total stockholders’ equity 700.0 696.7 Total liabilities and stockholders’ equity $ 1,445.2 $ 1,433.6 Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months Ended March 31, 2024 2023 ($ in millions) Cash flows from operating activities: Net income $ 0.9 $ 3.2 Adjustments to reconcile net income to net cash provided by operating activities Depreciation and amortization 7.8 7.8 Amortization of debt related costs 0.4 0.3 Stock-based compensation 1.8 1.5 Deferred tax (benefit) expense (0.5 ) 0.3 Other (0.3 ) — Changes in assets and liabilities, net of acquisitions Accounts receivable, net of allowances (9.7 ) (6.7 ) Prepaid expenses and other assets 3.7 18.1 Accounts payable 1.4 2.3 Accrued payroll 10.7 12.2 Other liabilities 1.1 (9.4 ) Net cash provided by operating activities 17.3 29.6 Cash flows from investing activities: Acquisition of businesses, net of cash acquired — (2.8 ) Purchases of property and equipment, including capitalized software costs (1.8 ) (0.6 ) Other 0.7 0.2 Net cash used in investing activities (1.1 ) (3.2 ) Cash flows from financing activities: Principal payments on debt (5.0 ) (5.0 ) Payments on revolving credit facility — (5.0 ) Principal payments under finance lease obligations (1.0 ) (1.0 ) Distributions paid to noncontrolling interests of consolidated affiliates — (2.5 ) Other (0.6 ) (0.5 ) Net cash used in financing activities (6.6 ) (14.0 ) Increase in cash, cash equivalents, and restricted cash 9.6 12.4 Cash, cash equivalents, and restricted cash at beginning of year 29.8 27.2 Cash, cash equivalents, and restricted cash at end of period $ 39.4 $ 39.6 Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Diluted Earnings Per Share to Adjusted Earnings Per Share Three Months Ended March 31, 2024 2023 Diluted earnings per share, as reported $ 0.01 $ 0.05 Adjustments, net of tax: Unusual or nonrecurring items that are not typical of ongoing operations(1) 0.06 0.03 Income tax adjustments(2) 0.01 0.01 Adjusted earnings per share(3) $ 0.07 $ 0.09 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. (2) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. (3) Adjusted EPS may not sum due to rounding. Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share Three Months Ended March 31, 2024 Adjustments As Reported Unusual or nonrecurring items that are not typical of ongoing operations Income tax Adjustments(3) As Adjusted ($ in millions, except per share data) Adjusted EBITDA(1) $ 25.3 $ — $ — $ 25.3 Interest expense and amortization of debt discounts and fees (11.1 ) — — (11.1 ) Depreciation and amortization (7.8 ) — — (7.8 ) Unusual or nonrecurring items that are not typical of ongoing operations(2) (3.7 ) 3.7 — — Stock-based compensation (1.8 ) — — (1.8 ) Gain on disposal or impairment of assets 0.2 — — 0.2 Income before income taxes 1.1 3.7 — 4.8 Income tax expense (0.9 ) (0.9 ) 0.6 (1.2 ) Net income attributable to Enhabit, Inc. $ 0.2 $ 2.8 $ 0.6 $ 3.6 Diluted EPS(4) $ 0.01 $ 0.06 $ 0.01 $ 0.07 Diluted shares 50.4 50.4 (1) Reconciliation to GAAP provided below. (2) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism. (3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. (4) Diluted EPS may not sum due to rounding. Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share Three Months Ended March 31, 2023 Adjustments As Reported Unusual or nonrecurring items that are not typical of ongoing operations Income Tax Adjustments(3) As Adjusted ($ in millions, except per share data) Adjusted EBITDA(1) $ 25.3 $ — $ — $ 25.3 Depreciation and amortization (7.8 ) — — (7.8 ) Interest expense and amortization of debt discounts and fees (9.5 ) — — (9.5 ) Stock-based compensation (1.5 ) — — (1.5 ) Unusual or nonrecurring items that are not typical of ongoing operations(2) (2.3 ) 2.3 — — Income before income taxes 4.2 2.3 — 6.5 Income tax expense (1.5 ) (0.6 ) 0.4 (1.7 ) Net income attributable to Enhabit, Inc. $ 2.7 $ 1.7 $ 0.4 $ 4.8 Diluted EPS(4) $ 0.05 $ 0.03 $ 0.01 $ 0.09 Diluted shares 50.1 50.1 (1) Reconciliation to GAAP provided below. (2) Unusual or nonrecurring items in Q1 2023 include nonroutine litigation, shareholder activism and standalone transition costs. (3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. (4) Diluted EPS may not sum due to rounding. Reconciliation of Net Income to Adjusted EBITDA Three Months Ended March 31, 2024 2023 ($ in millions) Net income $ 0.9 $ 3.2 Income tax expense 0.9 1.5 Interest expense and amortization of debt discounts and fees 11.1 9.5 Depreciation and amortization 7.8 7.8 Gain on disposal or impairment of assets (0.2 ) — Stock-based compensation 1.8 1.5 Net income attributable to noncontrolling interests (0.7 ) (0.5 ) Unusual or nonrecurring items that are not typical of ongoing operations(1) 3.7 2.3 Adjusted EBITDA $ 25.3 $ 25.3 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA Three Months Ended March 31, 2024 2023 ($ in millions) Net cash provided by operating activities $ 17.3 $ 29.6 Current portion of income tax expense 1.4 1.2 Interest expense, excluding amortization of debt discounts and fees 10.7 9.5 Change in assets and liabilities, excluding derivative instrument (7.2 ) (16.5 ) Net income attributable to noncontrolling interests (0.7 ) (0.5 ) Unusual or nonrecurring items that are not typical of ongoing operations(1) 3.7 2.3 Other 0.1 (0.3 ) Adjusted EBITDA $ 25.3 $ 25.3 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow Three Months Ended March 31, 2024 2023 ($ in millions) Net cash provided by operating activities $ 17.3 $ 29.6 Unusual or nonrecurring items that are not typical of ongoing operations(1) 3.7 2.3 Capital expenditures for maintenance (1.8 ) (0.6 ) Other working capital adjustments (0.6 ) (0.5 ) Distributions paid to noncontrolling interests of consolidated affiliates — (2.5 ) Adjusted free cash flow $ 18.6 $ 28.3 (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. Reconciliation of Gross Margin to Adjusted EBITDA Margin Three Months Ended March 31, 2024 2023 Gross margin as a percentage of revenue 48.9 % 50.0 % General and administrative expenses (41.0 )% (41.7 )% Unusual or nonrecurring items that are not typical of ongoing operations(1) 1.4 % 0.9 % Stock-based compensation 0.7 % 0.5 % Noncontrolling interests (0.3 )% (0.2 )% Gain on disposal or impairment of assets (0.1 )% — % Adjusted EBITDA margin 9.6 % 9.5 % (1) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism; in Q1 2023, they include nonroutine litigation, shareholder activism and standalone transition costs. FORWARD-LOOKING STATEMENTS Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and health care professionals; potential disruptions or breaches of our or our vendors’, payors’, and other contract counterparties’ information systems; the outcome of litigation; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; our ability to control costs, particularly labor and employee benefit costs; and impacts resulting from the announcement of the conclusion of the strategic review process. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company’s website at http://investors.ehab.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240508764297/en/
Investor relations contact Crissy Carlisle investorrelations@ehab.com 469-860-6061 Media contact Erin Volbeda media@ehab.com 972-338-5141
